Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Intangibles (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Intangibles for 16 consecutive years, with $218000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Intangibles changed N/A to $218000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $218000.0, a N/A change, with the full-year FY2024 number at $58.5 million, changed 0.35% from a year prior.
  • Intangibles was $218000.0 for Q3 2025 at Harvard Bioscience, down from $60.1 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $63.7 million in Q2 2022 to a low of $196000.0 in Q3 2023.
  • A 5-year average of $39.6 million and a median of $58.4 million in 2024 define the central range for Intangibles.
  • Peak YoY movement for Intangibles: skyrocketed 10681.5% in 2021, then decreased 23.26% in 2022.
  • Harvard Bioscience's Intangibles stood at $27.4 million in 2021, then fell by 23.26% to $21.0 million in 2022, then soared by 179.14% to $58.7 million in 2023, then fell by 0.35% to $58.5 million in 2024, then tumbled by 99.63% to $218000.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Intangibles are $218000.0 (Q3 2025), $60.1 million (Q2 2025), and $58.5 million (Q4 2024).